Table 3 Treatment-emergent Adverse Events That Occurred in ≥10% of Patients
TEAEa | Patients Treated With Lenvatinib 24 mg Once Daily (N = 26) | |
|---|---|---|
Patients with any-grade TEAE, n (%) | 26 (100) | |
Patients with any TEAE ≥ grade 3, n (%) | 21 (80.8) | |
Preferred term, n (%) | Any grade | Grade 3 or 4 |
Hypertension | 22 (84.6) | 10 (38.5) |
Dysphonia | 16 (61.5) | 0 |
Proteinuria | 16 (61.5) | 3 (11.5) |
Palmar-plantar erythrodysesthesia syndrome | 15 (57.7) | 3 (11.5) |
Decreased appetite | 14 (53.8) | 3 (11.5) |
Thrombocytopenia | 14 (53.8) | 1 (3.8) |
Fatigue | 13 (50.0) | 0 |
Hypothyroidism | 12 (46.2) | 0 |
Peripheral edema | 9 (34.6) | 0 |
Constipation | 8 (30.8) | 0 |
Decreased weight | 8 (30.8) | 0 |
Diarrhea | 8 (30.8) | 1 (3.8) |
Pyrexia | 8 (30.8) | 0 |
Anemia | 6 (23.1) | 3 (11.5) |
Cholangitis | 6 (23.1) | 4 (15.4) |
Nausea | 6 (23.1) | 0 |
Rash | 6 (23.1) | 1 (3.8) |
Upper abdominal pain | 6 (23.1) | 0 |
Malaise | 5 (19.2) | 0 |
Ascites | 4 (15.4) | 2 (7.7) |
Cancer pain | 4 (15.4) | 0 |
Headache | 4 (15.4) | 0 |
Myalgia | 4 (15.4) | 0 |
Stomatitis | 4 (15.4) | 0 |
Tumor pain | 4 (15.4) | 0 |
Alopecia | 3 (11.5) | 0 |
Bile duct obstruction | 3 (11.5) | 2 (7.7) |
Delirium | 3 (11.5) | 0 |
Epistaxis | 3 (11.5) | 0 |
Hypoalbuminemia | 3 (11.5) | 2 (7.7) |
Hypophosphatemia | 3 (11.5) | 1 (3.8) |
Lymphopenia | 3 (11.5) | 2 (7.7) |
Pruritis | 3 (11.5) | 0 |
Vomiting | 3 (11.5) | 0 |